This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, multicenter study designed to assess the efficacy, safety, tolerability, and pharmacokinetics (PK) of LB-102 100 mg once daily (QD) and LB-102 50 mg QD versus placebo QD for the treatment of adult patients with an acute exacerbation of schizophrenia
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Able to provide ICF
Willing to be hospitalized for duration of the study
Diagnosis of schizophrenia as defined by DSM-5
BMI - 18-40
PANSS 80-120
You may not be if
Sexually active m/f not willing to adhere to highly effect birth control
Breast feeding
Increase in PANSS of \> 20% between screening and baseline
History of resistant treatment to schizophrenia medications
DSM-5 diagnosis other than schizophrenia
Risk of suicidal behavior
Risk of violent or destructive behavior
Clinically significant tardive dyskinesia determined by a score of ≥3 on Item 8 of the AIMS at Screening
Score of ≥3 on the BARS global clinical assessment of akathisia at Screening
Insulin dependent diabetes
Known ischemic heart disease or any history of myocardial infarction, congestive heart failure (whether controlled or uncontrolled), angioplasty, stenting, or coronary artery bypass surgery
History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the patient